ABOS Acumen Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1576885 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY22.0%
TTM EPS YoY29.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-162.7%
ROA-91.3%
ROIC (approx.)-195.6%
Asset turnover—
Leverage & solvency
Liabilities / assets59.6%
Debt / equity0.76x
Current ratio1.89x
Interest coverage-24.65x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $21.11M | $27.81M | $16.48M | $20.53M | $21.97M | $37.12M | $25.27M | $34.57M |
| SG&A expense | $4.70M | $4.75M | $4.67M | $4.67M | $4.54M | $4.62M | $5.10M | $5.03M |
| Operating income | -$25.81M | -$32.56M | -$21.15M | -$25.20M | -$26.51M | -$41.75M | -$30.37M | -$39.60M |
| Interest expense | $999,000 | $1.09M | $1.07M | $1.09M | $1.07M | $1.05M | $1.02M | $1.04M |
| Net income | -$25.37M | -$32.72M | -$20.74M | -$25.14M | -$26.45M | -$40.95M | -$28.80M | -$37.15M |
| EBITDA | -$25.80M | -$32.55M | -$21.14M | -$25.19M | -$26.50M | -$41.73M | -$30.36M | -$39.58M |
| EPS (basic) | -0.35 | -0.45 | -0.33 | — | -0.44 | -0.68 | -0.48 | — |
| EPS (diluted) | -0.35 | -0.45 | -0.33 | — | -0.44 | -0.68 | -0.48 | — |
| Weighted avg. shares (diluted) | 72.32M | 72.25M | 63.22M | — | 60.57M | 60.57M | 60.53M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $53.08M | $59.44M | $51.80M | $53.99M | $47.06M | $37.04M | $30.39M | $35.86M |
| Short-term investments | $25.53M | $50.75M | $76.60M | $62.88M | $79.78M | $106.56M | $118.99M | $135.93M |
| Current assets | $85.13M | $115.51M | $133.09M | $122.25M | $132.15M | $148.40M | $154.95M | $178.31M |
| PP&E, net | $68,000 | $80,000 | $91,000 | $103,000 | $115,000 | $130,000 | $137,000 | $73,000 |
| Total assets | $85.56M | $116.01M | $133.63M | $122.83M | $142.22M | $171.90M | $204.48M | $238.99M |
| Current liabilities | $45.09M | $46.85M | $29.23M | $30.01M | $21.96M | $24.86M | $19.32M | $27.61M |
| Short-term debt | $20.40M | $19.67M | $14.12M | $8.77M | $3.60M | — | — | $0 |
| Long-term debt | $5.87M | $11.90M | $16.92M | $22.40M | $27.05M | $29.88M | $29.53M | $29.42M |
| Total debt | $26.27M | $31.57M | $31.05M | $31.16M | $30.65M | $29.88M | $29.53M | $29.42M |
| Total liabilities | $50.95M | $58.74M | $46.15M | $52.40M | $49.05M | $54.82M | $48.96M | $57.18M |
| Shareholders' equity | $34.61M | $57.26M | $87.48M | $70.43M | $93.17M | $117.08M | $155.52M | $181.82M |
| Net debt | -$26.80M | -$27.87M | -$20.75M | -$22.83M | -$16.41M | -$7.16M | -$863,000 | -$6.44M |
| Shares outstanding | 72.33M | 72.31M | 72.23M | 60.58M | 60.57M | 60.57M | 60.57M | 60.09M |
| Cash flow statement | ||||||||
| Operating cash flow | -$26.65M | -$18.07M | -$24.13M | -$19.10M | -$30.49M | -$31.83M | -$34.12M | -$27.21M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $9,000 | $79,000 | $0 |
| Free cash flow | -$26.65M | -$18.07M | -$24.13M | -$19.10M | -$30.49M | -$31.84M | -$34.20M | -$27.21M |
| Investing cash flow | $25.25M | $26.00M | -$13.81M | $26.25M | $40.51M | $38.48M | $28.69M | $29.66M |
| Financing cash flow | -$4.96M | -$278,000 | $35.74M | $2,000 | $0 | $0 | -$36,000 | -$9,000 |
| Depreciation & amortization | $12,000 | $11,000 | $12,000 | $12,000 | $15,000 | $16,000 | $15,000 | $14,000 |
| Stock-based compensation | $2.71M | $2.52M | $2.40M | $2.42M | $2.46M | $2.50M | $2.47M | $2.34M |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.